Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dolby Laboratories, Inc. (DLB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Dolby Laboratories, Inc.Trade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Dolby Laboratories, Inc. vs Neurocrine Biosciences Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.38 (market cap $5.75B), while Neurocrine Biosciences Inc trades at $158.84 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.9× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

DLBNBIX
Market Cap
$5.75B$16.46B
Sector
IndustrialsHealth
52-Week High
$75.62$185.50
52-Week Low
$48.51$123.10
Enterprise Value
$5.12B$16.48B
Dividend Yield
2.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dolby Laboratories, Inc.

DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.

The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX